Artículo original
Coste-efectividad de la combinación dutasterida y tamsulosina en el tratamiento de la hiperplasia benigna de próstata en España
Cost-Effectiveness of the Combination Therapy of Dutasteride and Tamsulosin in the Treatment of Benign Prostatic Hyperlasia in Spain
F. Antoñanzasa, F. Brenesb, J.M. Moleroc, A. Fernández-Prod, A. Huertae, R. Palenciae, J.M. Cozarf,
Autor para correspondencia
a Departamento de Economía Aplicada, Universidad de la Rioja, Logroño, España
b Centro de Atención Primaria Llefià (ABS6), Badalona, Barcelona, España
c Centro de Salud San Andrés, Madrid, España
d Centro de Salud de Menasalbas, Toledo, España
e GlaxoSmithKline, Tres Cantos, Madrid, España
f Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, España
Leído
4210
Vecesse ha leído el artículo
666
Total PDF
3544
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 1 | 1 |
| 2025 11 | 0 | 27 | 27 |
| 2025 10 | 0 | 6 | 6 |
| 2025 9 | 0 | 12 | 12 |
| 2025 8 | 0 | 2 | 2 |
| 2025 7 | 0 | 2 | 2 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 4 | 4 |
| 2025 4 | 0 | 2 | 2 |
| 2025 3 | 0 | 3 | 3 |
| 2025 1 | 0 | 9 | 9 |
| 2024 12 | 0 | 2 | 2 |
| 2024 9 | 0 | 1 | 1 |
| 2024 7 | 0 | 1 | 1 |
| 2024 6 | 0 | 2 | 2 |
| 2024 5 | 0 | 1 | 1 |
| 2024 3 | 0 | 4 | 4 |
| 2024 2 | 0 | 1 | 1 |
| 2024 1 | 0 | 4 | 4 |
| 2023 12 | 0 | 2 | 2 |
| 2023 11 | 0 | 1 | 1 |
| 2023 10 | 0 | 2 | 2 |
| 2023 9 | 0 | 13 | 13 |
| 2023 8 | 0 | 1 | 1 |
| 2023 7 | 0 | 3 | 3 |
| 2023 6 | 0 | 1 | 1 |
| 2023 5 | 0 | 1 | 1 |
| 2023 3 | 2 | 0 | 2 |
| 2023 2 | 0 | 2 | 2 |
| 2022 12 | 0 | 1 | 1 |
| 2022 10 | 0 | 2 | 2 |
| 2022 9 | 0 | 8 | 8 |
| 2022 8 | 0 | 4 | 4 |
| 2022 7 | 0 | 3 | 3 |
| 2021 11 | 0 | 1 | 1 |
| 2021 9 | 0 | 1 | 1 |
| 2021 7 | 1 | 1 | 2 |
| 2021 6 | 0 | 1 | 1 |
| 2020 12 | 0 | 1 | 1 |
| 2020 8 | 0 | 2 | 2 |
| 2020 7 | 0 | 1 | 1 |
| 2020 6 | 0 | 2 | 2 |
| 2020 5 | 0 | 1 | 1 |
| 2020 1 | 0 | 2 | 2 |
| 2019 12 | 1 | 2 | 3 |
| 2019 11 | 0 | 2 | 2 |
| 2019 8 | 0 | 4 | 4 |
| 2019 7 | 0 | 3 | 3 |
| 2019 6 | 0 | 6 | 6 |
| 2019 5 | 0 | 6 | 6 |
| 2019 4 | 0 | 7 | 7 |
| 2019 3 | 0 | 1 | 1 |
| 2019 2 | 0 | 1 | 1 |
| 2018 12 | 0 | 3 | 3 |
| 2018 2 | 15 | 1 | 16 |
| 2018 1 | 13 | 1 | 14 |
| 2017 12 | 8 | 0 | 8 |
| 2017 11 | 23 | 2 | 25 |
| 2017 10 | 7 | 3 | 10 |
| 2017 9 | 15 | 2 | 17 |
| 2017 8 | 19 | 1 | 20 |
| 2017 7 | 9 | 3 | 12 |
| 2017 6 | 23 | 12 | 35 |
| 2017 5 | 19 | 6 | 25 |
| 2017 4 | 10 | 3 | 13 |
| 2017 3 | 23 | 46 | 69 |
| 2017 2 | 15 | 5 | 20 |
| 2016 1 | 9 | 2 | 11 |
| 2016 12 | 24 | 5 | 29 |
| 2016 11 | 34 | 6 | 40 |
| 2016 10 | 31 | 13 | 44 |
| 2016 9 | 31 | 4 | 35 |
| 2016 8 | 35 | 7 | 42 |
| 2016 7 | 24 | 1 | 25 |
| 2016 6 | 21 | 13 | 34 |
| 2016 5 | 24 | 19 | 43 |
| 2016 4 | 21 | 19 | 40 |
| 2016 3 | 24 | 17 | 41 |
| 2016 2 | 14 | 21 | 35 |
| 2015 1 | 19 | 22 | 41 |
| 2015 12 | 21 | 18 | 39 |
| 2015 11 | 21 | 8 | 29 |
| 2015 10 | 26 | 17 | 43 |
| 2015 9 | 16 | 9 | 25 |
| 2015 8 | 14 | 7 | 21 |
| 2015 7 | 11 | 11 | 22 |
| 2015 6 | 12 | 5 | 17 |
| 2015 5 | 10 | 3 | 13 |
| 2015 4 | 21 | 24 | 45 |
| 2015 3 | 20 | 5 | 25 |
| 2015 2 | 14 | 8 | 22 |
| 2015 1 | 36 | 7 | 43 |
| 2014 12 | 52 | 15 | 67 |
| 2014 11 | 36 | 5 | 41 |
| 2014 10 | 55 | 16 | 71 |
| 2014 9 | 33 | 7 | 40 |
| 2014 8 | 38 | 5 | 43 |
| 2014 7 | 35 | 7 | 42 |
| 2014 6 | 32 | 9 | 41 |
| 2014 5 | 26 | 5 | 31 |
| 2014 4 | 16 | 8 | 24 |
| 2014 3 | 26 | 10 | 36 |
| 2014 2 | 24 | 3 | 27 |
| 2014 1 | 18 | 5 | 23 |
| 2013 12 | 12 | 5 | 17 |
| 2013 11 | 26 | 10 | 36 |
| 2013 10 | 25 | 7 | 32 |
| 2013 9 | 18 | 5 | 23 |
| 2013 8 | 20 | 6 | 26 |
| 2013 7 | 15 | 4 | 19 |
| 2011 2 | 2301 | 0 | 2301 |
Mostrar todo
